---
title: "NCEL.US (NCEL.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NCEL.US/news.md"
symbol: "NCEL.US"
name: "NCEL.US"
parent: "https://longbridge.com/en/quote/NCEL.US.md"
datetime: "2026-05-21T18:45:11.739Z"
locales:
  - [en](https://longbridge.com/en/quote/NCEL.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NCEL.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NCEL.US/news.md)
---

# NCEL.US (NCEL.US) — Related News

### [U.S. stock market update: NewcelX down 16.10%, financial losses and worsening financing environment raise market concerns](https://longbridge.com/en/news/284913942.md)
*2026-05-01T15:13:10.000Z*
> NewcelX fell 16.10%; Amgen fell 4.89%, with a trading volume of USD 375 million; Cue BioPharma rose 97.52%, with a tradi

### [12 Health Care Stocks Moving In Thursday's Intraday Session](https://longbridge.com/en/news/284813053.md)
*2026-04-30T17:05:55.000Z*
> In Thursday's trading session, several health care stocks experienced significant movements. Akanda (AKAN) surged 64.1% 

### [](https://longbridge.com/en/news/284805734.md)
*2026-04-30T15:55:43.000Z*
> NewcelX shares are trading higher after the company reported a year-over-year increase in FY EPS results. The company an

### [EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug](https://longbridge.com/en/news/284765384.md)
*2026-04-30T12:01:09.000Z*
> NewcelX Ltd. (NASDAQ:NCEL) reported its 2025 financial results, highlighting progress in its Type 1 diabetes program, NC

### [NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | NCEL Stock News](https://longbridge.com/en/news/284767049.md)
*2026-04-30T04:15:41.000Z*
> NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Di

### [Top NewcelX Insiders Quietly Make Bold Moves With Fresh Share Purchases](https://longbridge.com/en/news/284676946.md)
*2026-04-30T02:02:47.000Z*
> NewcelX (NCEL) insiders have made significant share purchases, with Director Samuel Olivier buying 81,818 shares for $22

### [NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | NCEL Stock News](https://longbridge.com/en/news/283345845.md)
*2026-04-20T03:37:00.000Z*
> NewcelX Ltd. (Nasdaq: NCEL) has updated its corporate presentation to emphasize its strategic collaboration with Eledon